Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001213900-25-014469·Brio Capital Master Fund Ltd.
Schedule 13G ownership disclosure
Sigyn Therapeutics Inc
COMMON STOCK, PAR VALUE $0.0001 · CUSIP: 82674U205
Event date: 2024-11-19
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Brio Capital Master Fund Ltd.
Shares: 158,932.00 · Class: 9.99%
- Brio Capital Management LLC
Shares: 158,932.00 · Class: 9.99%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-25-014469
- Form type
- SCHEDULE 13G/A
- Filer
- Brio Capital Master Fund Ltd.
- CIK
- CIK 1560894
- Filed
- Feb 14, 2025
- Reporting period
- Nov 19, 2024
- Description
- Schedule 13G beneficial ownership